Finbar Larkin - Mar 3, 2023 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role: SVP, Technical Operations
Signature: By: /s/Adam Guttmann, as attorney in fact For: Finbar Larkin
Stock symbol: JAZZ
Transactions as of: Mar 3, 2023
Transactions value $: -$437,430
Form type: 4
Date filed: 3/7/2023, 08:33 PM
Previous filing: Nov 16, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JAZZ	Ordinary Shares	Award	$0	+4.37K	+22.45%	$0.00	23.9K	Mar 3, 2023	Direct	F1, F2
transaction	JAZZ	Ordinary Shares	Options Exercise	$100K	+1.71K	+7.15%	$58.72	25.6K	Mar 6, 2023	Direct
transaction	JAZZ	Ordinary Shares	Sale	-$246K	-1.71K	-6.67%	$143.92	23.9K	Mar 6, 2023	Direct
transaction	JAZZ	Ordinary Shares	Sale	-$292K	-2.08K	-8.7%	$140.76	21.8K	Mar 7, 2023	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JAZZ	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-1.71K	-100%	$0.00^*	0	Mar 6, 2023	Ordinary Shares	1.71K	$58.72	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
F2	Includes 72 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2022.
F3	Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F4	Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $140.7578 to $140.7656 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5	These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vested over four years measured from the grant date, May 3, 2013, with 1/4th vesting on April 9, 2014 and the remainder vesting in 36 equal monthly installments thereafter. The option is fully vested and exercisable as of the date of this Form.